Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 21, 2026

Qualcomm Stockholders Back Board, Equity Plan; CEO Amon Highlights AI, Robotics and Data Center Push

View original at finance.yahoo.com
Qualcomm Stockholders Back Board, Equity Plan; CEO Amon Highlights AI, Robotics and Data Center Push Qualcomm logo Key Points Stockholders approved all board-recommended items including the election of 11 directors, ratification of PwC as auditor, approval of the amended 2023 long-term incentive plan with a 24 million…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Qualcomm is returning approximately 100% of free cash flow to shareholders

    60% confidence

  • Qualcomm expects data center revenue to become financially material in fiscal 2027

    60% confidence

  • Qualcomm has formally entered advanced robotics with Dragonwing IQ 10 series support for AMRs and humanoids

    60% confidence

  • Qualcomm is diversifying beyond handsets into personal AI, wearables, PCs, automotive, edge networking and industrial IoT

    60% confidence

Data points we hold from this source

Qualcomm Incorporated · dividend per share increase0.03 USD
Qualcomm Incorporated · board size11 directors
Qualcomm Incorporated · free cash flow return rate100 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com
Qualcomm Stockholders Back Board, Equity Plan; CEO Amon Highlights AI, Robotics and Data Center Push — Source | Via News | Via News